• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    6/20/24 1:26:29 PM ET
    $ALUR
    $AMD
    $APLD
    $ASNS
    Medical/Dental Instruments
    Health Care
    Semiconductors
    Technology
    Get the next $ALUR alert in real time by email

    Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results.

    Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from Benzinga Pro.

    Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22).

    Jabil shares dipped 7.8% to $116.37 on Thursday.

    Here are some other stocks moving in today’s mid-day session.

    Gainers

    • MGO Global, Inc. (NASDAQ:MGOL) shares jumped 222.8% to $1.48 after the company said it expects the pending acquisition of Spetner Associates to close in the second half of 2024, projecting it to increase annualized revenue to approximately $28 million.
    • Griid Infrastructure Inc. (NASDAQ:GRDI) climbed 89.3% to $1.48 after falling more than 10% on Tuesday.
    • Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) gained 89% to $2.58 after the company said it expects first customer deliveries of the i300 in the fourth quarter and anticipates selling over 5,000 units in the fiscal year ending September 30, 2025.
    • Reliance Global Group, Inc. (NASDAQ:RELI) shares climbed 60.5% to $0.6279. Reliance Global Group announced major enhancement of capital structure following cashless exercise of warrants.
    • Allurion Technologies Inc. (NYSE:ALUR) gained 50% to $1.598. Allurion announced publication of new data demonstrating lean mass gains in patients experiencing 14% weight loss.
    • SMX (Security Matters) Public Limited Company (NASDAQ:SMX) rose 43% to $0.1702 after jumping 19% on Tuesday.
    • Soluna Holdings, Inc. (NASDAQ:SLNH) gained 23.3% to $5.96.
    • Femasys Inc. (NASDAQ:FEMY) rose 22% to $1.1650 after receiving CE Mark approval from the EU MDR for its FemaSeed, FemVue, FemCerv, and FemCath products.
    • Molecular Partners AG (NASDAQ:MOLN) shares rose 21.1% to $9.63 after gaining 9% on Tuesday.
    • Surf Air Mobility Inc. (NASDAQ:SRFM) jumped 20.6% to $0.3850.
    • ToughBuilt Industries, Inc. (NASDAQ:TBLT) gained 20.2% to $3.75.
    • MicroCloud Hologram Inc. (NASDAQ:HOLO) surged 19.7% to $1.1303. MicroCloud Hologram entered into convertible note purchase agreements with investors for $28 million on June 18.
    • Presto Automation Inc. (NASDAQ:PRST) shares climbed 19.2% to $0.0877after falling around 5% on Tuesday.
    • NanoViricides, Inc. (NASDAQ:NNVC) gained 16.5% to $1.91. Nanoviricides reported that the ultra-broad-spectrum antiviral NV-387, a Phase 2 Stage drug candidate, was found to be effective in protecting lungs from damage in a lethally infected influenza H3N2 mouse model.
    • Lobo EV Technologies Ltd. (NASDAQ:LOBO) rose 16.4% to $2.47.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) gained 16% to $6.36 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $7 to $11.
    • Applied Digital Corporation (NASDAQ:APLD) jumped 15.3% to $5.95.
    • Ranpak Holdings Corp. (NYSE:PACK) climbed 13.7% to $6.49.
    • ImmunityBio, Inc. (NASDAQ:IBRX) rose 13.6% to $7.08 after the company announced insurance coverage of ANKTIVA across multiple states with first commercial doses administered.
    • Harrow, Inc. (NASDAQ:HROW) gained 12.2% to $19.81 after the company announced the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. Also the company announced that the second and third required PPQ batches are now scheduled.
    • ZKH Group Limited (NYSE:ZKH) rose 11.4% to $3.92
    • NANO Nuclear Energy Inc. (NASDAQ:NNE) gained 11.3% to $12.91.
    • Himax Technologies, Inc. (NASDAQ:HIMX) jumped 11.1% to $8.23
    • UTime Limited (NASDAQ:WTO) surged 11% to $0.5849
    • Nexalin Technology, Inc. (NASDAQ:NXL) gained 10% to $1.1450. Nexalin Technology shares jumped around 38% on Tuesday after the company was awarded a US patent on ‘Transcranial alternating current dynamic frequency stimulation (TACS) method for Alzheimers and Dementia.’
    • Bilibili Inc. (NASDAQ:BILI) shares climbed 7.8% to $17.45. On Tuesday, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price target.
    • Super Micro Computer, Inc. (NASDAQ:SMCI) gained 7% to $982.60 after Elon Musk indicated the company will provide server racks for the supercomputer that xAI is building.
    • Advanced Micro Devices, Inc. (NASDAQ:AMD) rose 5% to $162.36.

    Losers

    • Trevena, Inc. (NASDAQ:TRVN) fell 43.7% to $0.1993. Trevena announced preclinical TRV045 data for long-term analgestic effect in prelinical model of neuropathic pain. Also, the company announced TRV045 results provided director for additional NIH-initiated studies in epilepsy prevention and treatment.
    • Kaival Brands Innovations Group, Inc (NASDAQ:KAVL) shares declined 33.5% to $2.99 after gaining 8% on Tuesday.
    • Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) fell 29% to $1.10. Sonnet BioTherapeutics announced exercise of warrants for gross proceeds of $3.4 million.
    • Tempest Therapeutics, Inc. (NASDAQ:TPST) declined 25% to $2.1208. The company announced new data from the ongoing Phase 1b/2 clinical study on amezalpat2 (TPST-1120).
    • Nikola Corporation (NASDAQ:NKLA) declined 23.6% to $0.3672. Nikola announced 1-for-30 reverse stock split approved by board.
    • La Rosa Holdings Corp. (NASDAQ:LRHC) shares fell 23.5% to $1.37. La Rosa Holdings shares jumped 72% on Tuesday after the company entered a non-binding letter of intent to acquire a controlling interest in Red Door Title.
    • SYLA Technologies Co., Ltd. (NASDAQ:SYT) dipped 21.7% to $1.70.
    • Mustang Bio, Inc. (NASDAQ:MBIO) shares dipped 21% to $0.6721 after the company announced a $2.5 million registered direct offering of 6.130 million shares at $0.41 per share.
    • QXO, Inc. (NASDAQ:QXO) fell 20.9% to $72.55.
    • NLS Pharmaceutics AG (NASDAQ:NLSP) tumbled 20.3% to $0.1910 after jumping 82% on Tuesday.
    • DermTech, Inc. (NASDAQ:DMTK) fell 19.4% to $0.1176.
    • Dunxin Financial Holdings Limited (NASDAQ:DXF) shares fell 19.4% to $0.1728 after dipping 17% on Tuesday.
    • Tempus AI, Inc (NASDAQ:TEM) fell 15.1% to $25.76 amid post-IPO volatility.
    • Esperion Therapeutics, Inc. (NASDAQ:ESPR) declined 15% to $2.2991 after B of A Securities downgraded the stock from Neutral to Underperform.
    • SRIVARU Holding Limited (NASDAQ:SVMH) shares fell 13.7% to $0.2150. SRIVARU, last week, announced it will begin accepting paid reservations and bookings for its flagship product, the PRANA 2.0, on June 16th.
    • Actelis Networks, Inc. (NASDAQ:ASNS) fell 12.2% to $1.8602. Actelis Networks shares jumped 84% on Tuesday after the company announced an agreement to serve as Carahsoft’s public sector distributor.
    • Jasper Therapeutics, Inc. (NASDAQ:JSPR) declined 10.1% to $20.84. Jasper Therapeutics announced appointment of Svetlana Lucas Ph.D., to its Board of Directors.
    • GMS Inc. (NYSE:GMS) declined 6.5% to $84.02 after the company reported mixed fourth-quarter financial results.
    • Nayax Ltd. (NASDAQ:NYAX) fell 6.1% to $21.23.
    • Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) fell 5% to $6.03 after the company’s board determined that recent takeover proposals were not in its best interests.

    Now Read This: This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

    Get the next $ALUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALUR
    $AMD
    $APLD
    $ASNS

    CompanyDatePrice TargetRatingAnalyst
    Vanda Pharmaceuticals Inc.
    $VNDA
    3/5/2026$18.00Buy
    Truist
    Tempus AI Inc.
    $TEM
    2/19/2026$100.00Outperform
    Mizuho
    Tempus AI Inc.
    $TEM
    2/17/2026$59.00Outperform
    Robert W. Baird
    Advanced Micro Devices Inc.
    $AMD
    2/13/2026$220.00Neutral
    DA Davidson
    Himax Technologies Inc.
    $HIMX
    2/4/2026$8.00Overweight → Equal-Weight
    Morgan Stanley
    Molecular Partners AG
    $MOLN
    1/27/2026$13.00Buy
    H.C. Wainwright
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    Jasper Therapeutics Inc.
    $JSPR
    1/13/2026$17.00Buy
    Rodman & Renshaw
    More analyst ratings

    $ALUR
    $AMD
    $APLD
    $ASNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Legal Officer Signorello Christopher J.

    4 - QXO, Inc. (0001236275) (Issuer)

    3/9/26 6:19:05 PM ET
    $QXO
    RETAIL: Building Materials
    Consumer Discretionary

    Director Gliedman Michael S. was granted 3,750 shares, increasing direct ownership by 2% to 173,013 units (SEC Form 4)

    4 - Ranpak Holdings Corp. (0001712463) (Issuer)

    3/9/26 4:52:19 PM ET
    $PACK
    Containers/Packaging
    Consumer Discretionary

    Chief Financial Officer & EVP Drew William was granted 4,602 shares, increasing direct ownership by 0.83% to 561,848 units (SEC Form 4)

    4 - Ranpak Holdings Corp. (0001712463) (Issuer)

    3/9/26 4:49:41 PM ET
    $PACK
    Containers/Packaging
    Consumer Discretionary

    $ALUR
    $AMD
    $APLD
    $ASNS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALUR
    $AMD
    $APLD
    $ASNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Vanda Pharma with a new price target

    Truist initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    3/5/26 8:32:16 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Tempus AI with a new price target

    Mizuho initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $100.00

    2/19/26 7:52:33 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Robert W. Baird initiated coverage on Tempus AI with a new price target

    Robert W. Baird initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $59.00

    2/17/26 8:19:06 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $ALUR
    $AMD
    $APLD
    $ASNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $15,605 worth of Class A Shares (14,584 units at $1.07) and sold $9,121 worth of Class A Shares (8,368 units at $1.09), increasing direct ownership by 15% to 48,596 units (SEC Form 4)

    4 - La Rosa Holdings Corp. (0001879403) (Issuer)

    3/3/26 2:57:47 PM ET
    $LRHC
    Real Estate
    Finance

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Tempus Ai, Inc. bought $2,739,181 worth of shares (320,267 units at $8.55), increasing direct ownership by 3% to 13,039,067 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    2/13/26 5:24:46 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    $ALUR
    $AMD
    $APLD
    $ASNS
    SEC Filings

    View All

    SEC Form 10-K filed by Esperion Therapeutics Inc.

    10-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

    3/10/26 4:55:11 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    3/10/26 4:47:06 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Digital Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits

    8-K - Applied Digital Corp. (0001144879) (Filer)

    3/10/26 4:15:40 PM ET
    $APLD
    Finance: Consumer Services
    Finance

    $ALUR
    $AMD
    $APLD
    $ASNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

    -- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the initiation of patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc. This milestone follows U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to advance the study based on positive clinical data generated in its

    3/10/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

    3/10/26 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to three newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of March 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 60,175 shares of Ocular's common stock and re

    3/9/26 4:01:00 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALUR
    $AMD
    $APLD
    $ASNS
    Financials

    Live finance-specific insights

    View All

    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

    3/10/26 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Himax to Showcase WiseEye AIoT Solutions, Industry Leading Automotive Display IC and Innovative Optical Technologies at Embedded World 2026

    TAINAN, Taiwan, March 09, 2026 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. ("Himax" or "Company") (NASDAQ:HIMX), an industry leader in fabless display driver ICs and semiconductors, today announced participation in Embedded World 2026, a world-leading trade show for embedded electronics and industrial computing, taking place in Nürnberg, Germany, from March 10 - 12, 2026. Through a series of live demonstrations and technology showcases, Himax will highlight its WiseEye ultralow power endpoint AI innovations, the most comprehensive, market-leading automotive display IC portfolio, as well as state-of-the-art optical technologies. A key focus of the showcase will be the versatile deployment

    3/9/26 4:35:00 AM ET
    $HIMX
    Semiconductors
    Technology

    Ranpak Holdings Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

    Net revenue for the fourth quarter increased 6.6% year over year to $111.9 million and increased 2.2% year over year on a constant currency basis Net loss for the fourth quarter of $9.5 million compared to net loss of $8.0 million for the prior year period Adjusted EBITDA ("AEBITDA") for the fourth quarter of $24.0 million down 5.1%, or $1.3 million, year over year, down 10.3% on a constant currency basis Ranpak Holdings Corp (NYSE:PACK) ("Ranpak" or "the Company"), a leading provider of environmentally sustainable, systems-based, product protection and end-of-line automation solutions for e-commerce and industrial supply chains, today reported its fourth quarter 2025 financial re

    3/5/26 7:30:00 AM ET
    $PACK
    Containers/Packaging
    Consumer Discretionary

    $ALUR
    $AMD
    $APLD
    $ASNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Kaival Brands Innovations Group Inc.

    SC 13D/A - Kaival Brands Innovations Group, Inc. (0001762239) (Subject)

    12/12/24 7:22:30 PM ET
    $KAVL
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by SYLA Technologies Co. Ltd.

    SC 13D/A - SYLA Technologies Co., Ltd. (0001946216) (Subject)

    12/10/24 6:03:39 AM ET
    $SYT
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALUR
    $AMD
    $APLD
    $ASNS
    Leadership Updates

    Live Leadership Updates

    View All

    NANO Nuclear Expands its Nuclear Policy Leadership Expertise with the Appointment of U.S. Government Veteran Sarah Lennon as its International Nuclear Policy Advisor

    New York, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ:NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear micro modular reactor (MMR) and technology company focused on developing clean energy solutions, today announced the appointment of Sarah Lennon as its International Nuclear Policy Advisor. Sarah is a seasoned national security and nuclear energy policy leader with three decades of distinguished service across the U.S. Government, bringing deep expertise in nuclear security, nonproliferation, international cooperation, and strategic planning. "It is a pleasure to join the NANO Nuclear team," said Sarah Lennon, International Nuclear Policy A

    2/20/26 8:30:00 AM ET
    $NNE
    Electric Utilities: Central
    Utilities

    FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.

    Oran Muduroglu, proven medical imaging entrepreneur, to lead U.S. launch of eyonis® LCS Established U.S. commercial and clinical infrastructure combined with Medicare reimbursement pathway already in place to support expansion Active discussions underway to establish key clinical partnerships to support broad access across U.S. lung cancer screening programs Webcasts will be held on February 26, 2026, to discuss the Company's recent achievements and upcoming milestones for eyonis® LCS deployment in the U.S. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218440005/en/Oran Muduroglu Appointed Presi

    2/18/26 11:45:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    AMD Hires Ariel Kelman as Chief Marketing Officer

    SANTA CLARA, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Today AMD (NASDAQ:AMD) announced that Ariel Kelman has been appointed Senior Vice President and Chief Marketing Officer, effective immediately. Kelman will lead the AMD global marketing organization, overseeing brand, communications, events, developer relations and go-to-market strategy. Kelman will report to Ruth Cotter, Senior Vice President and Chief Administrative Officer, and will work closely with the AMD executive team to deepen engagement with customers, partners, developers and the broader technology ecosystem as AMD continues to scale its product and solutions leadership. "Ariel is a proven marketing leader with deep experi

    2/9/26 2:00:00 PM ET
    $AMD
    Semiconductors
    Technology